LOQTORZI
These highlights do not include all the information needed to use LOQTORZI safely and effectively. See full prescribing information for LOQTORZI. LOQTORZI (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023
Approved
Approval ID
82e7921a-1e84-4988-9799-0ad7d19b2a75
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Nov 27, 2023
Manufacturers
FDA
Coherus BioSciences, Inc.
DUNS: 078502849
Products 1
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
toripalimab-tpzi
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code70114-340
Application NumberBLA761240
Product Classification
M
Marketing Category
C73585
G
Generic Name
toripalimab-tpzi
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 23, 2023
FDA Product Classification
INGREDIENTS (1)
toripalimabActive
Quantity: 240 mg in 6 mL
Code: 8JXN261VVA
Classification: ACTIB